

REMARKS

Claims 1 to 43 were pending in this application. Claims 32 to 42 have been withdrawn from further consideration as being directed to a non-elected invention. Claim 18 has been canceled without prejudice. Applicants reserve the right to prosecute the subject matter of the canceled claim in the present application and/or one or more related applications. Claims 1, 2, 4, 9, 12, 19, 20, 24 and 43 have been amended. The amended claims are fully supported by the specification as originally filed, see, *e.g.*, the table below for examples of support in the specification for the amended claims.

| <u>Claim No.</u> | <u>Examples of Support in Specification</u> |
|-------------------------|---|
| 1 | page 2, ¶ 8; pages 7 to 8, ¶ 23; page 11, ¶ 32; page 12, ¶ 37 to page 13, ¶ 38; pages 80 to 81, ¶ 206 |
| 2 | page 2, ¶ 8; page 7, ¶ 22; page 65, ¶ 159; page 12, ¶ 37 to page 13, ¶ 38; pages 80 to 81, ¶ 206 |
| 4 | page 5, ¶ 19 |
| 9 | page 59, ¶ 144 |
| 12 | page 10, ¶ 29 |
| 19 | page 11, ¶ 32 |
| 20 | pages 64 to 65, ¶ 158 |
| 24 | page 11, ¶ 32 |
| 43 | pages 80 to 81, ¶ 206 |

Thus, no new matter has been added. After entry of the present Amendment, claims 1 to 17, and 19 to 43 will be pending in the instant application.

The Examiner has required an election under 35 U.S.C. § 121 and § 372 of one of the following groups:

- Group I: Claims 1-31 and 43, drawn to a method for identifying a compound that modulates untranslated region-dependent expression of a vascular endothelial growth factor (VEGF);
- Group II: Claim 32, drawn to a method of modulating the expression of VEGF gene;
- Group III: Claims 33, 37, and 42, drawn to a method of treating, preventing, or ameliorating cancer;

Group IV: Claims 34, 38, and 41, drawn to a method of inhibiting or reducing angiogenesis; and

Group V: Claims 35, 36, 39, and 40, drawn to a method of identifying a compound that inhibits or reduces angiogenesis.

In response, Applicants hereby elect to prosecute the claims of Group I, drawn to a method for identifying a compound that modulates untranslated region-dependent expression of a VEGF.

Applicants respectfully request entry of the amendments and remarks made herein into the file history of the present application. The Examiner is invited to contact the undersigned with any questions concerning the foregoing.

Respectfully submitted,

Date: November 17, 2008

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)
JONES DAY
222 East 41st Street
New York, NY 10017
(212) 326-3939

By: Jennifer J. Chade
Reg No. 46,617